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DObjectives: In the Surgical Treatment for Ischemic Heart Failure trial, surgical ventricular reconstruction plus
coronary artery bypass surgery was not associated with a reduction in the rate of death or cardiac hospitalization
compared with bypass alone. We hypothesized that the absence of viable myocardium identifies patients with
coronary artery disease and left ventricular dysfunction who have a greater benefit with coronary artery bypass
graft surgery and surgical ventricular reconstruction compared with bypass alone.
Methods:Myocardial viability was assessed by single photon computed tomography in 267 of the 1000 patients
randomized to bypass or bypass plus surgical ventricular reconstruction in the Surgical Treatment for Ischemic
Heart Failure. Myocardial viability was assessed on a per patient basis and regionally according to prespecified
criteria.
Results: At 3 years, there was no difference in mortality or the combined outcome of death or cardiac
hospitalization between those with and without viability, and there was no significant interaction between the
type of surgery and the global viability status with respect to mortality or death plus cardiac hospitalization.
Furthermore, there was no difference in mortality or death plus cardiac hospitalization between those with
and without anterior wall or apical scar, and no significant interaction between the presence of scar in these
regions and the type of surgery with respect to mortality.
Conclusions: In patients with coronary artery disease and severe regional left ventricular dysfunction,
assessment of myocardial viability does not identify patients who will derive a mortality benefit from adding
surgical ventricular reconstruction to coronary artery bypass graft surgery. (J Thorac Cardiovasc Surg
2014;148:2677-84)See related commentary on pages 2684-5.
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The Surgical Treatment for Ischemic Heart Failure
(STICH) trial demonstrated that in patients with ischemic
cardiomyopathy and anterior wall akinesis undergoing
coronary artery bypass grafting (CABG), the addition of
surgical ventricular reconstruction (SVR) was not associ-
ated with a reduction in the rate of death or hospitalization
for cardiac causes compared with results of CABG alone.1
All patients in the SVR hypothesis of STICH were required
to have global left ventricular (LV) dysfunction (ejection
fraction 35%) and regional dysfunction with anteriordiovascular Surgery c Volume 148, Number 6 2677
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
CAD ¼ coronary artery disease
LV ¼ left ventricular
SPECT ¼ single photon emission computed
tomography
STICH ¼ Surgical Treatment for Ischemic Heart
Failure
SVR ¼ surgical ventricular reconstruction
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Dakinesia or dyskinesia, as determined by the recruiting
investigators. However, whether these dysfunctional seg-
ments were composed of scarred or viable myocardium
was not analyzed in the original report, because systematic
application of a dedicated test for myocardial viability was
not part of the original study design or a determinant of
treatment assignment.
Although viable myocardium is expected to recover after
revascularization, scarred tissue is not. Further, a large amount
of scarred myocardium may contribute negatively to overall
LV function by accelerating or worsening the process of
remodeling and by reducing the mechanical contribution of
normal or viable myocardium via tethering of adjacent seg-
ments. Therefore, excluding scarred anterior wall segments
through SVR could result in hemodynamic and clinical
improvement. Conversely, identification of myocardial
viability in the same areas could lead to the retention of seg-
ments with the potential to recover after revascularization
without SVR and contribute to improved LV mechanical
function. Accordingly, distinguishing between viable versus
scarredmyocardium in theLV territory targeted for reconstruc-
tion may be critical for the success of the procedure and could
identify apopulationwhowill preferentiallybenefit fromSVR.
Single photon emission computed tomography (SPECT) is
commonly performed in patients with LV dysfunction being
considered for revascularization to identify areas of viable
and scarred myocardium. Therefore, we tested in the STICH
population the hypothesis that the presence of myocardial
scar on SPECT identifies patients with coronary artery
disease (CAD) and LV dysfunction who have the greatest
benefit with CABG þ SVR compared with CABG alone.METHODS
Study Design
The rationale and design of the STICH trial have been described,1-3 as
have the methods of the viability substudy of the STICH revascularization
hypothesis.4 STICH was a multicenter, nonblinded, randomized trial
sponsored by the National Heart, Lung, and Blood Institute. A total of
2136 patients were enrolled at 127 sites in 26 countries, all of whom
were candidates for CABG. STICH involved 2 hypotheses regarding the
role of surgery in patients with LV systolic dysfunction. All patients in
STICH were eligible for CABG on the basis of clinical and coronary
angiographic findings. The STICH revascularization hypothesis enrolled2678 The Journal of Thoracic and Cardiovascular Surpatients whowere candidates for CABG or medical therapy, thus excluding
patients with left main disease or unstable angina.3 The STICH SVR
hypothesis enrolled patients who were candidates for CABG who also
had severe regional dysfunction of the LV anterior wall and were eligible
for SVR.1 In this arm of the trial, 1000 patients were enrolled, of whom
499 were assigned to CABG alone and 501 were assigned to CABG plus
SVR. Myocardial viability testing was performed using SPECT in 267 of
the 1000 patients, of whom 126 were assigned to CABG alone and 141
were assigned to CABG plus SVR. An independent core laboratory funded
by the National Heart, Lung, and Blood Institute, in which investigators
were unaware of study group assignments and the individual characteristics
of patients, coordinated data collection and analysis for the SPECT studies.Study Procedures
Four different clinically validated SPECTprotocols for assessingmyocar-
dial viability were permitted at the enrolling sites. These included thallium
imaging using a rest-redistribution or stress-rest-reinjection protocol,5 a
dual isotope protocol with rest-redistribution thallium imaging plus stress
imaging with a technetium-99m perfusion tracer,6 or imaging with a
technetium-99m tracer at rest after the administration of nitroglycerin.7
Images were stored digitally and sent to the STICH Radionuclide Core
Laboratory atNorthwesternUniversity for analysis.Core laboratorymeasure-
ment of regional tracer activity was performed on all SPECT studies using a
17-segment model of the left ventricle.8 A myocardial segment was deemed
viable if the tracer activity in that segment was 50% or greater of the activity
in the segment with maximal activity. For thallium rest-redistribution
imaging, a segment with activity less than 50% of the maximal myocardial
activity on the redistribution imageswas also defined as viable if the improve-
ment in activity from the rest to redistribution images was 12% or greater.
Segments not meeting these criteria for viability were deemed to be scarred.
Myocardial viability on a per-patient basis was prospectively defined as
the presence of 11 or more viable segments (65% of the entire left
ventricle). When 7 or more segments were nonviable (41% of the left
ventricle), the patient was considered to have insufficient mass of viable
myocardium. This threshold was selected on the basis of previous
retrospective data indicating that the likelihood for functional improvement
afterCABGis lowwhenmore than40%of theLVmyocardium is nonviable.9
Because the SVR procedure involves reconfiguring the anteroapical
wall, we specifically explored the impact of anterior wall and apical
scarring on the outcomes with CABG alone and CABG þ SVR. For this
analysis, viability was assessed using a 5-segment model in which the
left ventricle was divided into septal, inferior, lateral, anterior, and apical
segments (Figure E1).
Patient Follow-up and Outcomes
After enrollment, patients were followed every 4 months for the first
year and every 6 months thereafter. The primary outcome was the
composite of death from any cause or hospitalization for cardiovascular
causes. The secondary end point was death from any cause. Definitions
of the trial end points have been reported.3 All end points were adjudicated
by an independent clinical events committee. The comparisons of
outcomes that were related to treatment were based on intention-to-treat
analyses. Analyses that were based on actual treatment received were
also performed to account for crossovers.
Statistical Analysis
Baseline patient characteristics are summarized as percentages for
categoric variables and means and standard deviations for continuous
variables. Comparisons of baseline data between (a) patientswith andwithout
a viability test, and (b) patients with and without myocardial viability, given
that a test was obtained, were performed using the Pearson chi-square test
for categoric variables and the Wilcoxon rank-sum test for continuous vari-
ables. Kaplan–Meier event curves for mortality and for death or cardiacgery c December 2014
TABLE 1. Baseline characteristics of patients in Surgical Treatment
for Ischemic Heart Failure surgical ventricular reconstruction
hypothesis with and without viability testing: Clinical characteristics
Variable
Patients
with a
viability
test (n ¼ 267)
Patients
without a
viability test
(n ¼ 733)
P
value
Age, mean  SD 61.3  9.5 61.8  9.8 .627
Female, n (%) 40 (15.0) 107 (14.6) .880
Diabetes, n (%) 77 (28.8) 267 (36.4) .026
Hyperlipidemia, n (%) 184 (69.4) 534 (73.0) .275
Hypertension, n (%) 132 (49.4) 453 (61.8) <.001
Current smoker, n (%) 50 (18.7) 167 (22.8) .169
Chronic renal insufficiency,
n (%)
21 (7.9) 64 (8.7) .671
Atrial flutter/fibrillation,
n (%)
28 (10.5) 89 (12.1) .471
Peripheral vascular disease,
n (%)
37 (13.9) 109 (14.9) .688
Prior myocardial infarction,
n (%)
237 (88.8) 635 (86.6) .372
Risk-at-randomization score,*
median (Q1, Q3)
10.0 (4.0, 19.0) 13.0 (6.0, 22.0) .002
Previous PCI, n (%) 67 (25.1) 128 (17.5) .007
Previous CABG, n (%) 2 (0.7) 22 (3.0) .040
Previous ICD, n (%) 5 (1.9) 29 (4.0) .108
CCS angina class, n (%) .001
No angina 51 (19.1) 198 (27.0)
I 20 (7.5) 51 (7.0)
II 72 (27.0) 116 (15.8)
III 106 (39.7) 302 (41.2)
IV 18 (6.7) 66 (9.0)
NYHA HF class, n (%) <.001
I 20 (7.5) 66 (9.0)
II 154 (57.7) 275 (37.5)
III 80 (30.0) 348 (47.5)
IV 13 (4.9) 44 (6.0)
Blood pressure, mean  SD .007
Systolic 117.7  15.7 121.6  18.1
Diastolic 73.9  9.9 73.3  11.7
Heart rate, mean  SD 72.1  11.9 72.7  14.0 .628
Creatinine (mg/dL) 1.1  0.4 1.1  0.4 .324
CAD distribution, n (%)
Left main (50%) 42 (15.7) 155 (21.1) .057
No. of vessels>50% .084
1-Vessel 32 (12.0) 55 (7.5)
2-Vessel 70 (26.2) 205 (28.0)
3-Vessel 165 (61.8) 473 (64.5)
Previous CABG, n 2 22 .007
Bypass graft status, n (%)
1 Stenosed or occluded 2 (100) 18 (81.8)
1 Occluded 2 (100) 15 (68.2)
LVEF, mean  SD 27.3  5.5 26.8  6.0 .236
EDVI mL/m2, mean  SD 122.7  46.4 114.9  40.8 .045
ESVI mL/m2, mean  SD 87.6  39.5 90.2  36.4 .027
ACEI/ARB 246 (92.1) 633 (86.4) .013
Beta-blocker 232 (86.9) 576 (78.6) .551
(Continued)
TABLE 1. Continued
Variable
Patients
with a
viability
test (n ¼ 267)
Patients
without a
viability test
(n ¼ 733)
P
value
Amiodarone 31 (11.6) 93 (12.7) .648
Aspirin 215 (80.5) 593 (80.9) .084
Warfarin 26 (9.7) 96 (13.1) .151
Clopidogrel 19 (7.1) 62 (8.5) .491
Digoxin 43 (16.1) 114 (15.6) .832
Diuretic (loop/thiazide) 143 (53.6) 452 (61.7) .021
Diuretic (potassium sparing) 112 (41.9) 259 (35.3) .056
Nitrate 165 (61.8) 422 (57.6) .230
Statin 230 (86.1) 541 (73.8) <.001
ACEI, Angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor
blocker; CABG, coronary artery bypass grafting; CAD, coronary artery disease;
EDVI, end-diastolic volume index; ESVI, end-systolic volume index; ICD, implant-
able cardiac defibrillator; LVEF, left ventricular ejection fraction; NYHA HF,
New York Heart Association heart failure; PCI, percutaneous coronary intervention;
SD, standard deviation; CCS, Canadian Cardiovascular Society. *The risk-at-
randomization score ranges from 1 to 32, with higher numbers indicating a higher pre-
dicted rate of death.
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Dhospitalization were created and displayed by groups, and the log-rank test
was used to statistically compare groups with respect to these outcomes.
Among the patients with viability assessment, unadjusted and adjusted
Cox proportional hazards regression models were used to examine the
association between the status of myocardial viability and the outcomes
of death and death or cardiac hospitalization. The adjustment variables
were baseline clinical factors, including age, creatinine, atrial fibrillation/
flutter, diabetes, mitral regurgitation, and end-systolic volume index,
known from previous analyses to be key prognostic factors.
The Cox model was also used to examine the association between the
randomized treatments (CABG vs CABG þ SVR) and the 2 outcomes,
death and death or cardiac hospitalization, in patients with and without
viable myocardium. Hazard ratios and 95% confidence intervals for the
treatment comparisons were generated using the Cox model. The Cox
model was also used to test for an interaction between treatment and
viability, that is, whether there was a different effect of CABG þ SVR
compared with CABG alone in patients with versus those without viability.
These analyses were performed for overall LV viability, anterior wall
viability, apex viability, and the anterior wall and apex combined. All
statistical tests were 2-sided. All statistical analyses were performed using
SAS statistical software, version 9.2 (SAS Institute Inc, Cary, NC).RESULTS
Study Population
Among the 267 patients with a viability assessment, 227
were men and 40 were women. The mean age was 61  9
years, the mean LV ejection fraction was 27%  5%, and
89% of patients had a previous myocardial infarction.
Table 1 shows a comparison of the baseline characteristics
of the patients who underwent a SPECT viability study
and those who did not. Both groups were similar in age,
gender, history of myocardial infarction, CAD distribution,
and ejection fraction. Of note, the patients who underwent
viability testing less often had a history of diabetes,
hypertension, or prior CABG and more often had
undergone prior percutaneous coronary intervention. Those
who did not undergo viability testing had a higher clinicaldiovascular Surgery c Volume 148, Number 6 2679
TABLE 2. Baseline characteristics of patients who underwent
viability testing: Clinical characteristics
Variable
Patients
without
myocardial
viability (n ¼ 76)
Patients with
myocardial
viability
(n ¼ 191)
P
value
Age, y, mean  SD 61.7  8.7 61.1  9.8 .704
Female, n (%) 7 (9.2) 33 (17.3) .096
Prior myocardial infarction,
n (%)
72 (94.7) 165 (86.4) .051
Risk-at-randomization
score,* median (Q1, Q3)
11.0 (5.0, 21.0) 10.0 (4.0, 19.0) .526
CCS angina class, n (%) .614
No angina 13 (17.1) 38 (19.9)
I 3 (3.9) 17 (8.9)
II 23 (30.3) 49 (25.7)
III 31 (40.8) 75 (39.3)
IV 6 (7.9) 12 (6.3)
Highest NYHA HF class
within 3 mo, n (%)
.622
I 2 (2.6) 8 (4.2)
II 30 (39.5) 64 (33.5)
III 34 (44.7) 84 (44.0)
IV 10 (13.2) 35 (18.3)
ACEI/ARB 72 (94.7) 174 (91.1) .319
Beta-blocker 66 (86.8) 166 (86.9) .988
Aspirin 62 (81.6) 153 (80.1) .784
Statin 67 (88.2) 163 (85.3) .548
CAD distribution, n (%)
Left main (50%) 13 (17.1) 29 (15.2) .697
No. of vessels>75% .838
None 1 (1.3) 5 (2.6)
1-Vessel 18 (23.7) 42 (22.0)
2-Vessel 29 (38.2) 81 (42.4)
3-Vessel 28 (36.8) 63 (33.0)
LVEF, mean  SD 27.6  5.41 27.2  5.52 .649
EDVI mL/m2, mean  SD 143.1  53.23 114.6  40.83 <.001
ESVI mL/m2, mean  SD 111.9  47.51 84.6  38.18 <.001
ACEI, Angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker;
CAD, coronary artery disease; EDVI, end-diastolic volume index; ESVI, end-systolic
volume index; LVEF, left ventricular ejection fraction; NYHA HF, New York
Heart Association heart failure; SD, standard deviation; CCS, Canadian Cardiovascu-
lar Society. *The risk-at-randomization score ranges from 1 to 32, with higher
numbers indicating a higher predicted rate of death.
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Drisk at the time of randomization, as assessed using an
equation derived in an independent dataset from multiple
variables with known power to predict 5-year risk of death
without CABG.10
Myocardial Viability, Scar, and Outcomes
Myocardial viability was identified in 191 (72%) of
the study patients; the remaining 76were classified as nonvi-
able. Table 2 shows a comparison of the baseline character-
istics of the patients with and without myocardial viability.
Patients with and without viability were similar in age (61
10 years vs 62 9 years) and ejection fraction (27% 6%
vs 28% 5%). Patientswithout viability had larger LVend-2680 The Journal of Thoracic and Cardiovascular Surdiastolic and end-systolic volume indices than those with
viability (143  53 vs 115  41 mL/m2 and 112  48 vs
85  38 mL/m2, respectively; both P<.0001).
When treatment allocation was not considered, there was
no significant difference in mortality between patients with
and without viability (19% vs 22% at 3 years, P ¼ .84)
(Figure 1, A) or in the combined outcome of death or
cardiac hospitalization (48% vs 62% at 3 years, P ¼ .17)
(Figure 1, B).
Of the 267 patients with a viability test, predominantly
nonviable myocardium was identified in the anterior wall or
apex in 221 (83%). At 3 years, there was no difference in
mortality between thosewith and without nonviable myocar-
dium in the anterior wall (19% vs 21%, respectively,
P ¼ .85), apex (20% vs 23%, respectively, P ¼ .96), or the
combined anterior wall and apex (20% vs 22%, respectively,
P ¼ .89). There was also no difference between those with
viable versus nonviable myocardium in these territories for
the combined outcome of death or cardiac hospitalization.
Interaction Between Myocardial Viability and
Treatment
Among the 191 patients with myocardial viability, 99
(52%) underwent CABG þ SVR and 92 (48%) underwent
CABG alone. Of the 76 patients without viability, 42 (55%)
underwent CABG þ SVR and 34 (45%) underwent
CABG alone. There was no significant interaction between
global myocardial viability status and the treatment effect
of CABG þ SVR versus CABG alone with respect to
mortality (P ¼ .36) (Figure 2, A) or death plus cardiac
hospitalization (P ¼ .55) (Figure 2, B).
When regional viability was considered, there was no
significant interaction between the presence or absence of
viable myocardium in the anterior region and the type of
surgery with respect to mortality (P ¼ .12) (Figure 3, A).
There was no significant interaction between the presence
or absence of scar in the apical region and the treatment
effect of CABG þ SVR versus CABG alone with respect
to mortality (P¼ .55) (Figure 3, B) or death or cardiovascu-
lar hospitalization (P ¼ .70). Similar to the findings in the
apex, there was no significant interaction between the
presence or absence of viable myocardium in the combined
anterior wall and apex and the type of surgery with respect
to mortality (P¼ .78) (Figure 3, C) or death or cardiovascu-
lar hospitalization (P ¼ .67).
DISCUSSION
The original results of the SVR hypothesis of the STICH
trial demonstrated no survival benefit in adding SVR to
CABG.1 Uncertainty persists on whether certain subgroups
of patients may benefit from SVR, such as those with
larger LV volumes or those with evidence of scar in the
anteroapical region.11,12 In this substudy of the STICH
trial, we demonstrated that an overall assessment ofgery c December 2014
FIGURE 1. Kaplan–Meier estimates of the probability of death (A) and death or cardiovascular hospitalization (B) according tomyocardial viability status.
CI, Confidence interval; HR, hazard ratio.
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Dmyocardial viability with SPECT imaging does not
help predict which patients will be alive or free from
cardiac hospitalization 3 years after undergoing CABG
or CABG þ SVR or which patients will benefit
more from performing concomitant SVR at the time of
CABG. Furthermore, specifically identifying nonviable
myocardium in the anterior wall and apex did not help
determine which patients would derive a survival benefit
with SVR.
Our findings are similar to those of the viability substudy
of the STICH revascularization hypothesis, in which the
results of viability testing with SPECT or dobutamine
echocardiography were not associated with benefit from
adding CABG to optimal medical therapy.4 However, it
must be noted that this study addressed a completelyThe Journal of Thoracic and Cardifferent issue, namely, whether the presence of myocardial
viability or scar was associated with benefit from SVR in
patients in whom the decision for surgical revascularization
had already been made. Thus, in these patients, the
myocardial viability information would not be used to aid
in the decision between medical therapy alone or medical
therapy plus revascularization. Instead, the potential value
of noninvasive testing would derive from identifying areas
without viability (or with scar) that may be surgically
excluded from the LV cavity at the time of surgery to
improve LV performance and, ultimately, patient outcomes.
In this context, the results observed with the assessment of
global LV viability are not necessarily surprising and
suggest that this form of imaging is not helpful for the
selection of patients who benefit from adding SVR todiovascular Surgery c Volume 148, Number 6 2681
FIGURE 2. Kaplan–Meier estimates of the probability of death (A) and death or cardiovascular hospitalization (B) according to myocardial viability status
and treatment. CABG, Coronary artery bypass grafting; CI, confidence interval; SVR, surgical ventricular reconstruction.
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DCABG. It must be noted that previous studies of patient
outcomes with SVR did not report incorporation of viability
testing into the decision for SVR.13 Thus, it is unclear what
role noninvasive studies have played in the selection of
patients by other investigators.2682 The Journal of Thoracic and Cardiovascular SurOn the basis of the study design requiring all
patients to be eligible to undergo the SVR procedure,
it was expected that the majority of patients (82% in
the present study) demonstrated evidence of scar on
the apical segments. However, only 25% of the patientsgery c December 2014
FIGURE 3. Kaplan–Meier estimates of the probability of death according to anterior wall myocardial viability status and treatment (A), apical myocardial
viability status and treatment (B), and anterior or apical myocardial viability status and treatment (C). CABG, Coronary artery bypass grafting;
CI, confidence interval; SVR, surgical ventricular reconstruction.
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Dincluded in this substudy also had scar on the anterior
wall.Study Limitations
In this study, SPECT imaging was the only modality used
for assessing myocardial viability. Other commonly used
tests (eg, delayed enhancement cardiac magnetic resonance
imaging) have not been examined in the STICH trial. It is
possible that the more detailed and quantitative myocardial
scarring information provided by delayed enhancement
imaging with magnetic resonance would prove useful in
the selection of appropriate patients for SVR. This possibil-
ity deserves further investigation.
The SVR hypothesis of the STICH trial was not designed
to examine the impact of viability determination on
outcomes in these patients. The present observations are
based on a post hoc analysis of a subset of STICH patients
who underwent viability testing with SPECT. Thus, the
impact of these observations is reduced compared with a
trial specifically designed to address this issue. In addition,
the reduced number of patients limits the statistical power
of our findings. Finally, the decision to enroll patients in
this trial could have been influenced by prior viability
testing. However, it must be noted that the majority of
patients in this report had viability testing performed after
randomization.CONCLUSIONS
In patients with CAD and severe regional LV
dysfunction, assessment of myocardial viability does not
identify patients who will benefit in terms of survival
from adding SVR to CABG.EDITORIAL CO
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FIGUREE1. Five-segment model of the left ventricle used for analysis of
regional viability.
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